Comparison of p53 and CD44 variant 6 expression between paired primary and recurrent ovarian cancer: an immunohistochemical analysis

PURPOSE: To assess the effect of the injection rate of contrast medium on pancreatic and hepatic enhancement at abdominal helical computed tomography (CT). MATERIALS AND METHODS: Sixty-four contrast medium-enhanced abdominal helical CT scans (64 adult patients) were obtained with 150 mL of contrast medium. The injection rate was 2.5 mL/sec for the first 32 scans and 5.0 mL/sec for the remaining 32. Scans were obtained at 5-sec intervals, with an intermediate 8-sec breathing interval. Hepatic and pancreatic enhancement levels were measured and averaged, and time-attenuation curves were plotted for both groups. Differences in weight, age, time to peak pancreatic and hepatic enhancement, and peak enhancement were assessed with the Student t test. RESULTS: Both peak enhancement and time to peak enhancement were significantly different between the two injection rates (P < or = .002), with faster, more intense hepatic and pancreatic enhancement at the higher rate. At 2.5 mL/sec, the pancreas reached a peak attenuation level of 65 HU at 69 sec, and the liver reached a peak of 58 HU at 87 sec. At 5.0 mL/sec, the pancreas reached a peak attenuation of 84 HU at 43 sec, and the liver reached a peak of 75 HU at 63 sec.     

Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta

PURPOSE: To assess the severity of adverse reactions to contrast media in outpatient computed tomographic (CT) examinations in a conventional clinical setting. MATERIALS AND METHODS: In 4,936 patients, CT was performed with four protocols: ionic contrast medium with sodium meglumine as the cation (in one protocol, contrast material was warmed to 35 degrees C before injection; in another protocol, it was administered at ambient temperature); warmed, ionic contrast medium with nonsodium pure meglumine as the cation; and warmed, nonionic iopamidol. RESULTS: Adverse reactions to ionic contrast material statistically significantly decreased (P<.05) when it was warmed before administration. Reactions to ionic contrast media without a sodium cation were statistically significantly fewer (P<.001) than reactions to those with a sodium cation. In all protocols, pediatric patients had fewer reactions than adult patients. CONCLUSION: In outpatient CT examinations, nonionic, warmed contrast medium was the best option because no severe reactions resulted from its use. Prevalence of adverse reactions was comparable to that in controlled randomized studies.     

Glucose induces glucose 6-phosphatase hydrolytic subunit gene transcription in an insulinoma cell line (INS-1)

OBJECTIVE: The goal of our study was to determine the effect of contrast material injection rate and patient demographic variables on vascular enhancement for abdominal CT angiography and compare test injection results with actual patterns of vascular enhancement. SUBJECTS AND METHODS: One hundred twenty-five patients underwent abdominal CT angiography. For each patient, CT attenuation values (Hounsfield units) of the aorta were determined before and after IV contrast administration, every 3 sec between 21 and 60 sec. A peak aortic enhancement value and the time needed to reach peak and aortic enhancement thresholds of 150 and 200 H were determined. All patients received 150 ml of nonionic contrast material at 3 ml/sec in 25 patients and 4 ml/sec in 100 patients. A test injection of 15 ml was used to compute a scan delay in 46 patients. Patient age, sex, weight, injection rate, and test injection results were compared with vascular enhancement patterns. RESULTS: For the 125 patients, the mean aortic enhancement at each time point was greater than 150 H. Patient weight was inversely correlated (r2 = -.62) with aortic enhancement. The test injection did not accurately predict actual aortic enhancement peak value or time. Test injection delay time was significantly correlated with time to reach aortic enhancement thresholds of 150 and 200 H. The 4 ml/sec rate resulted in a higher peak aortic enhancement (320+/-58 H versus 281+/-49 H) (mean +/- SD, p < .01) that was reached quicker than with the 3 ml/sec injection rate (45+/-5 sec versus 52+/-5 sec) (p < .01). Injecting at 4 ml/sec resulted in greater aortic enhancement values at 24-45 sec, whereas 3 ml/sec produced significantly better aortic enhancement at 54-60 sec. CONCLUSION: The test injection correlated better with time to reach specific aortic enhancement thresholds than with time to peak aortic enhancement. For a given amount of contrast material, faster injection rates resulted in greater vascular enhancement that occurred earlier.     

Contrast media extravasation during dynamic CT: detection with an extravasation detection accessory

To detect extravasation of contrast media during mechanical power injection at dynamic computed tomography, a 5 x 8-cm pliable adhesive patch was applied to the skin over the intravenous cannula and connected to the power injector with a cable to monitor electrical skin impedance. If the rate of change or the slope of impedance over time indicated an extravasation event, the power injector was set into a pause mode. In animal and human studies, monitoring with the device was successful. Extravasation of ionic contrast agents decreased impedance and that of nonionic agents increased impedance.     

Primary central nervous system lymphoma in a child with acute B-cell lymphoblastic leukaemia: consecutive Epstein-Barr virus-related malignancies

OBJECTIVE: The aim of the study was to evaluate the optimization of injection rates with an automatic power injector versus manual injection for contrast-enhanced breath-hold three-dimensional (3D) MR angiography of the abdominal aorta and its branches. SUBJECTS AND METHODS: In a prospective study, 50 patients underwent breath-hold 3D MR angiography (5/2 [TR/TE]; flip angle, 30 degrees) of the abdominal vessels on a 1.5-T system. Each patient received 0.15 mmol/kg of gadopentetate dimeglumine. All patients were randomly assigned to one of five equally sized groups. The contrast bolus was injected manually in group 1, always by the same investigator, who tried to perform a steady injection rate of 2 ml/sec. An automatic injector was used in groups 2-5 with injection flow rates of 0.5 ml/sec, 2 ml/sec, 4 ml/sec, and 6 ml/sec. The start of the MR sequence was tailored individually to the applied volume of contrast material after determination of circulation times by a test bolus. We measured the signal-to-noise and contrast-to-noise ratios as well as the relative vascular enhancement. The visualization of different abdominal vessel segments was independently ranked on a scale of 1-5 (1 = not visible; 5 = excellent visualization) by three reviewers who were unaware of the applied contrast material injection rate. RESULTS: The signal-to-noise and contrast-to-noise ratios of groups 3 and 4 (2 ml/sec and 4 ml/sec, respectively) were significantly (p < .05) higher than the ratios of groups 1, 2, and 5. The average relative vascular enhancement of groups 3 and 4 was significantly higher (p < .05) than the enhancement of all other groups. The contrast bolus applied with a faster injection rate (group 5) did not cover large parts of the K-space, resulting in increased blurring of the vessel contours. The subjective evaluation of large and small diameter vessels showed significantly better results in groups 3 and 4 than in groups 1, 2, and 5. CONCLUSION: The use of an automatic MR power injector proved superior to manual injection of contrast material. The optimal injection rate was 2 ml/sec for 3D breath-hold MR angiography of the abdominal vessels.     

Contrast-medium-induced ventricular fibrillation: arrhythmogenic mechanisms and the role of antiarrhythmic drugs in dogs

RATIONALE AND OBJECTIVES: Small electrolyte additions to a nonionic contrast medium reduce the risk of ventricular fibrillation (VF) during wedged catheter injection of a contrast medium. The current study was designed to further investigate contrast-medium-induced VF by studying the effect of pretreatment with different antiarrhythmic drugs. METHODS: During a simulated wedged catheter situation, iohexol was injected into the anterior descending branch of the left coronary artery in five open-chest, anesthetized dogs pretreated with lidocaine, propranolol, amiodarone, almokalant, or verapamil. RESULTS: Wedging the catheter for 60 sec did not induce VF. However, all 15 wedged catheter injections with iohexol induced VF within 28 sec (19 +/- 1 [mean +/- standard error of the mean]) despite pretreatment with antiarrhythmic drugs. Prior to VF, conduction was slowed and monophasic action potential duration lengthened in the contrast-medium-perfused myocardium, although no significant changes occurred in the control area. CONCLUSION: The combination of catheter wedging and long-lasting contrast medium injection has a high risk of causing VF. Although adding a small amount of electrolytes to nonionic contrast media can reduce the risk of VF, antiarrhythmic drug therapy may not have a protective effect.     

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators

Restenosis after coronary angioplasty occurs in at least 30% of patients in the first six months and, as yet, there is no known treatment to decrease this event. We tested a monoclonal antibody Fab fragment (c7E3) directed against the platelet glycoprotein IIb/IIIa integrin, the receptor mediating the final common pathway of platelet aggregation, to see whether it reduced the frequency of clinical restenosis. Patients who had unstable angina, recent or evolving myocardial infarction, or high-risk angiographic morphology, were randomised to receive c7E3 bolus and a 12 hour infusion of c7E3 (708 patients), c7E3 bolus and placebo infusion (695 patients), or placebo bolus and placebo infusion (696 patients). With maintenance of the double-blind state, patients were followed-up for at least 6 months to determine the need for repeat angioplasty or surgical coronary revascularisation and the occurrence of ischaemic events. By 30 days, 12.8% of placebo bolus/placebo infusion patients had had a major ischaemic event (death, myocardial infarction, urgent revascularisation), compared with 8.3% of c7E3 bolus/c7E3 infusion patients, yielding a 4.5% difference (35% reduction, p = 0.008). At 6 months, the absolute difference in patients with major ischaemic event or elective revascularisation was 8.1% between placebo bolus/placebo infusion and c7E3 bolus/c7E3 infusion patients (35.1% vs 27.0%; 23% reduction p = 0.001). The favourable long-term effect was mainly due to less need for bypass surgery or repeat angioplasty in patients with an initial successful procedure, since need for repeat target vessel revascularisation was 26% less for c7E3 bolus/c7E3 infusion than for placebo treatment (16.5% vs 22.3%; p = 0.007). The c7E3 bolus/placebo infusion group had an intermediate outcome which was not significantly better than that of the placebo bolus/placebo infusion group. These results extend the benefit of c7E3 bolus/c7E3 infusion from reducing abrupt closure and acute-phase adverse outcomes to a diminished need for subsequent coronary revascularisation procedures. Because this therapy carries a risk of bleeding complications and has been studied only in high-risk angioplasty patients, further evaluation is needed before it can be applied to other patient groups.     

Diagnosis, treatment, and complications of thoracic outlet syndrome

BACKGROUND AND PURPOSE: The present study investigated the influence of the antiplatelet agent acetylsalicylic acid (ASA) on cerebral microembolism as detected by transcranial Doppler sonography (TCD). METHODS: Nine patients with recent transient ischemic attack or minor stroke of arterial origin were investigated. Eight had not received an antiplatelet or anticoagulant medication before TCD, and in 1 patient a preexisting ASA medication (100 mg/d) had not been changed since the onset of stroke symptoms. An initial 1-hour TCD monitoring was extended for an additional 2.5 hours after an intravenous bolus injection of 500 mg ASA and was repeated for 1 hour on the following day. RESULTS: Microembolic signals (MES) were detected in all patients only on the symptomatic side. After the ASA bolus injection, a significant drop of the MES rate was found in 7 patients, all without previous medication, starting 30 minutes after the application (mean per hour=25.1 [range, 6 to 66] versus mean per hour=6.4 [range, 0 to 14]). In 3 of these patients, platelet aggregation tests were performed that demonstrated normal aggregation before bolus injection and inhibited aggregability as early as 30 minutes after bolus injection. The rate of MES remained unchanged in 1 patient without antiplatelet medication. The ninth patient, who had suffered an ischemic event on ASA, showed only a transient decrease of MES frequency. CONCLUSIONS: In patients with recent stroke of arterial origin, intravenous ASA can rapidly reduce cerebral microemboli as detected by TCD. Microemboli might be a useful parameter to monitor early effects of antiplatelet therapy.     

Liver CT: a practical approach to dynamic contrast enhancement

The aim of this study was to establish a practical, simple protocol that reliably produces high quality dynamic incremental computed tomography (CT) of the liver. We reviewed 90 patients randomly allocated into six different protocols. All had preliminary unenhanced scans followed by a dynamic incremental CT of the liver. An initial delay of 30 seconds was used from the commencement of the injection of Iopamiro 370. The groups were: 1. Pump infusion (a) 100 mls at 2 mls/sec scanning inferosuperiorly. (b) 100 mls at 2 mls/sec scanning superoinferiorly. (c) 100 mls at 1 ml/sec scanning inferosuperiorly. (d) 50 mls at 1 ml/sec scanning inferosuperiorly. 2. 40 mls hand injected bolus followed immediately by 60 ml pump infusion at 1.3 mls/sec scanning inferosuperiorly. 3. 50 mls hand injected bolus scanning inferosuperiorly. The parameters recorded were the degree of hepatic parenchymal and hepatic venous enhancement and the aortic--IVC difference at the last slice through the liver, all measured in Hounsfield units. The protocols using 100 mls of contrast produced approximately twice the parenchymal and hepatic venous enhancement compared with those using 50 mls. Approximately 60-90% of examinations using 100 mls produced scans through the entire liver during the bolus or nonequilibrium phase, deemed the most sensitive for the detection of focal lesions, compared with 13-33% of those using 50 mls. Equally satisfactory results were obtained using the relatively inexpensive Biotel power injector preceded by a 40 ml hand injected bolus, compared with using an Angiomat angiography infusion pump.(ABSTRACT TRUNCATED AT 250 WORDS)     

Comparison of cardiovascular response to ionic and nonionic magnetic resonance susceptibility contrast agents

RATIONALE AND OBJECTIVES: Bolus injection of magnetic resonance (MR) contrast media has been used in recent years to exploit the diagnostic advantage of newer fast MR imaging sequences. The bolus effects of three equimolar dosages of ionic and nonionic magnetic susceptibility contrast agents on several cardiovascular functional parameters are investigated in normal rats and in rats subjected to acute myocardial infarction. These results are related to the osmolalities of the injected solutions. METHODS: Four groups of rats were examined (n = 10 rats per group). Twenty normal rats were studied. Acute myocardial infarction was produced by ligating the anterior branch of the left coronary artery for 2 hours in another 20 rats. Sequential equimolar doses of 0.1, 0.3, and 0.5 mmol/kg of ionic dysprosium diethylenetriamine pentaacetic acid dimeglumine ([NMG]2DyDTPA) or nonionic dysporosium diethylenetriamine pentaacetic acid-bis-methylamide (DyDTPA-BMA) (sprodiamide injection) were administered intravenously into the left jugular vein as a bolus. Hemodynamic parameters (heart rate, left ventricular pressures, rate of rise of left ventricular pressure [+/- dP/dt], and electrocardiogram as well as central and peripheral pressures) were continuously monitored for 15 minutes after each dose. Left ventricular developed pressure and rate pressure product, as indicators of myocardial oxygen consumption, were calculated. Osmolalities of the injected solutions were determined from freezing-point depression and correlated with the observed hemodynamic alterations. RESULTS: Bolus administration of 0.1, 0.3, and 0.5 mmol/kg DyDTPA-BMA produced no significant effect on the various hemodynamic parameters. (NMG)2DyDTPA caused dose-dependent attenuations in heart rate, left ventricular pressures, +/- dP/dt, rate pressure product and arterial blood pressures in both normal and infarcted rats. The magnitude of the response was dose dependent. Significant correlations were observed between osmolality and peak change of hemodynamic variables (r values between 0.99-1.00) after the administration of (NMG)2DyDTPA, but not after the injection of DyDTPA-BMA. CONCLUSIONS: Bolus administration of (NMG)2DyDTPA resulted in transient negative inotropic and chronotropic effects and hypotension in both healthy and infarcted animals. DyDTPA-BMA, administered as a bolus even at high doses, caused no appreciable hemodynamic alterations.     

Must the patient fast before intravascular injection of a non-ionic contrast medium? Results of a controlled study

PURPOSE: Prospective evaluation of food and fluid restriction before the intravascular injection of a non-ionic contrast medium. MATERIAL AND METHODS: 1000 patients (657 men, 343 women; average age 59 +/- 1/4 5 years) undergoing intravascular contrast injections (CT, phlebography, angiography, urography) were randomly allocated to two groups. Group A had no fluid or solids for at least four hours before the injection (499 cases); group B were allowed unlimited food and fluid (501 cases). Both groups were comparable in all other respects and all were given the non-ionic contrast medium iopamidol (300 mg l/ml). RESULTS: The incidence of acute complications was 3.5%. There was, however, no statistically significant difference between the two groups (p = 0.29). Late adverse reactions were seen in 3.9% patients. There was again no difference between the two groups (p = 0.33). No serious or life threatening complications occurred. CONCLUSION: Restriction of food and fluid before intravascular injection of contrast medium does not reduce the number of adverse side effects. For reasons of patient comfort and compliance, and to achieve adequate hydration, the patient should not fast before injection of contrast.     

The 2-His-1-carboxylate facial triad--an emerging structural motif in mononuclear non-heme iron(II) enzymes

PURPOSE: To determine in-line pressures generated in small-bore central venous catheters during power injection of computed tomographic (CT) contrast media. MATERIALS AND METHODS: Five 3.0-7.0-F central venous catheters for pediatric patients were tested at full and half lengths in vitro. In-line pressures were measured during power injection of three contrast media. Rates of injection were increased in steps from 0.1 to 5.0 mL/sec or until a peak pressure of 100 psi (700 kPa) was achieved. The maximum tolerated flow rate was determined with reference to the manufacturer's suggested operating pressure limit for each catheter. RESULTS: At full length, the maximum tolerated flow rates were as follows: 2-3 mL/sec for the large lumen and 1-1.4 mL/sec for the small lumen of the 7.0-F double-lumen catheter; 0.2-0.4 and 0.8-1.2 mL/sec for the 3.0- and 4.0-F peripherally inserted central catheters, respectively; 0.7-1.2 mL/sec for the 6.6-F catheter; and only 0.2 mL/sec for the 4.2-F catheter, which ruptured during testing at higher flow rates. CONCLUSION: Flow rates were documented at which certain small-bore central venous catheters should tolerate power injection of CT contrast media with peak pressures remaining below the manufacturer's recommended operating pressure limits. These data may serve as a guide for clinical use.     

Optimizing contrast enhancement during helical CT of the liver: a comparison of two bolus tracking techniques

OBJECTIVE: The purpose of this study was to evaluate a recently developed hardware and software system for CT scanning that generates images in real time and switches to helical CT scanning by either a visual cue or a region of interest (ROI) amplitude threshold. SUBJECTS AND METHODS: We randomly and prospectively divided 120 abdominal CT examinations into three groups. Two groups received 75 ml of contrast agent at 1.5 ml/sec. Helical CT scanning began after visualization of the contrast bolus arrival in the hepatic veins (visual cue triggering) (39 patients) or after reaching an ROI threshold (automated ROI threshold triggering) (39 patients). A third group served as a control group (42 patients) and received 150 ml of contrast agent at 1 ml/sec. Quality of hepatic enhancement was assessed objectively and subjectively. Comparisons were made after stratifying each group into three weight classes. RESULTS: Errors occurred in 12 (31%) of 39 examinations in the group with automated ROI threshold triggering. In that group, we found a significantly (p < .04) lower mean hepatic enhancement in two of three weight categories, and a significantly (p < .04) lower mean subjective scan quality in one of three weight categories, than we found in the group with visual cue triggering. CONCLUSION: Optimizing portal venous phase helical CT of the liver after a low-volume bolus of contrast agent and an injection rate of 1.5 ml/sec is best achieved by initiating helical CT scanning after visualizing the contrast bolus arrival within the liver rather than after reaching a preset attenuation threshold.     

Topoisomerase I inhibitor with potential radiosensitizing effect

The principal aim of this study was to evaluate, on biochemical grounds, whether injection of a low-osmolar nonionic contrast medium (iohexol) can induce a prothrombotic state and/or a change in fibrinolysis. Fifteen patients were submitted to urographic examination and the assays listed below were performed: before the injection (T0), 1 h after (T1), and 24 h after (T24) the injection of the contrast medium. The following assays were performed: fibrinopeptide A (FPA), prothrombin fragment 1+2 (F1+2), thrombin-antithrombin complex (TAT) and D dimer (D-D). The assays were carried out on 6 of the patients to whom a saline infusion was administered. Only a mild statistically significant increase was found in FPA levels at 1 h after injection of the contrast medium (mean and CI 95%: T0 4.4, 3.7-5.5; T1 6.0, 4.9-9.1; p = 0.003). F1+2, TAT and D-D did not show any significant change after the injection. These findings show that after injection of iohexol, only a mild, though statistically significant, increase in FPA levels was observed as an expression of increased thrombin activity. In the absence of any significant increases in TAT, F 1+2 and D-D, we have no evidence of a prethrombotic state.     

Aspirin and fraxiparine in the prevention of laser induced thrombosis in the presence of iodinated contrast media

The purpose of this study was to investigate the thromboembolic properties of ionic and nonionic contrast media in rats pretreated with aspirin and/or fraxiparine using an experimental model of laser induced thrombosis in the mesenteric microvessels of 17 groups of five male Wistar rats each. Two ionic (ioxaglate and diatrizoate) and two nonionic contrast media (iopamidol and iohexol), alone or associated with antithrombotic drugs (aspirin and/or fraxiparine) were studied. To evaluate the effects of these substances in this model, the number of laser beams needed to induce platelet thrombus formation, the number of emboli detached from the thrombus and the duration of embolization were quantified. Platelet aggregation induced by ADP, induced hemorrhagic time (IHT) and haemoglobin loss level were also determined. Both contrast media injected at 3 ml/kg caused a significant increase in the number of emboli and the duration of embolization (p<0.05). Pretreatment with aspirin and/or fraxiparine in the presence of ionic contrast media showed antithrombotic activities equal to those obtained when they were tested alone (p<0.05), while in the presence of nonionic contrast media, these drugs only neutralised the prothrombotic effects. There were no differences with the NaCl treated group (p>0.05). The ionic contrast media, and to a lesser extent the nonionic contrast medium: iohexol, inhibited platelet aggregation, while iopamidol behaved as an activator. The antithrombotic drugs tested in this study prevent the prothrombotic activities of contrast media therefore suggesting their use before radiographic procedures.     

Histamine release and contrast media-induced renal vasoconstriction

RATIONALE AND OBJECTIVES: The authors' purpose was to investigate the role of histamine release causing renal vasoconstriction induced by application of contrast media, an important element in contrast medium-induced nephrotoxicity. MATERIALS AND METHODS: Isometric contractions in rabbit segmental renal arteries stimulated with KCl and increasing concentrations of the ionic contrast medium diatrizoate and the nonionic agents iomeprol and iodixanol were studied both with and without increasing concentrations of the histamine H1 and H2 blockers diphenhydramine and cimetidine. Histamine concentrations after contrast medium application were determined. RESULTS: Contrast-induced, dose-dependent, reversible renal artery contractions of 27%, 4.5%, and 5% of the control KCl contraction were found for diatrizoate, iodixanol, and iomeprol respectively. Those induced by the ionic contrast medium were statistically significantly higher (P < .01). Contractions were partially inhibited by diphenhydramine (49%) but not by cimetidine. Significant elevation of histamine concentrations (P < .05) was detected only after stimulation with diatrizoate but not with nonionic agents. CONCLUSION: Ionic contrast medium induces histamine release leading to renal vasoconstriction, which can be partly blocked by H1 blockers. Histamine has no effect on renal vasospasm induced by nonionic contrast media.     

Lead levels in deciduous teeth of children from urban and suburban regions in Ankara (Turkey)

PURPOSE: To determine whether hyperglycemia affects pancreatic islet microcirculation in vivo and whether nitric oxide is a mediator. METHODS: Islet blood flow was measured before and after infusion of glucose during in vivo microscopy of mouse pancreatic islet. The pancreas of male BALB/c mice was exteriorized and viewed under the microscope utilizing monochromatic transmitted light. The carotid artery and tail vein were cannulated and systemic blood pressure was monitored continuously. Under fluorescent light, a 0.02 mL bolus of 2% fluorescein isothyocyanate (FITC-albumin) was injected intra-arterially and the first pulse of FITC-albumin through an islet capillary was videorecorded. Following equilibration, either glucose or normal saline 300 mg/g of body weight was given intravenously. Five minutes later, a second bolus was given and the second pulse was videorecorded. The study was repeated in the presence of N omega-nitro-L-arginine methyl ester (L-NAME). The FITC-albumin bolus mean transit time (TT) and observed cross time (OCT) through the islet were calculated using slow-motion video analysis of the recorded images. RESULTS: Infusion of glucose resulted in a significant increase in islet blood flow with no change in systemic blood pressure: baseline TT was 20 +/- 1.3 pixel/0.03 sec and baseline OCT was 0.6 +/- 0.04 seconds; during hyperglycemia, TT was 16.1 +/- 1 pixel/0.03 sec, and OCT was 0.48 +/- 0.03 seconds (n = 11, P < 0.05 versus basal via paired t-test). Continuous infusion of L-NAME negated the effect of hyperglycemia on islet blood flow: baseline TT was 20 +/- 1.8 pixel/0.03 sec and OCT was and 0.6 +/- 0.05 seconds; during hyperglycemia, TT was 20 +/- 1.1 pixel/0.03 sec and OCT was 0.6 +/- 0.33 seconds (n = 10; P < 0.05 versus glucose via unpaired t-test).     

The influence of polyethylene glycol conjugation on bovine hemoglobin's intrinsic effect on the gastrointestinal system of the rat

The purpose of this study was to determine the impact of polyethylene glycol (PEG) conjugation on bovine hemoglobin's effect on gastrointestinal (GI) blood flow and motility in the Sprague Dawley rat. This study was divided into two parts: part one assessed blood flow, while the other evaluated bolus transit time through the GI. To examine blood flow, thirty-two rats were divided into four experimental groups (PEG-hemoglobin, bovine hemoglobin, Ringer's Lactate and autologous blood sham). Blood flow within the superior mesenteric artery was monitored during graduated isovolemic hemodilution. In the second part of the study, GI motility was estimated by bolus transit time. Thirty-six rats were assigned to four groups (PEG-hemoglobin, bovine hemoglobin, Ringer's Lactate and no treatment sham) and following an overnight fast, the rats were given a bolus injection (25 mL/kg) of test article. Three hours following injection, they received an oral 0.3 mL gavage of a charcoal/arabic gum mixture and were later sacrificed and their GI tract evaluated. Results indicated that the infusion of bovine hemoglobin reduced both baseline blood flow through the mesenteric artery and gastrointestinal transit time. In contrast, PEG-hemoglobin maintained baseline blood flow through the mesenteric artery and had no effect on GI transit time or morphology. Therefore, PEG conjugation of bovine hemoglobin significantly attenuated its intrinsic effect on the GI system of the rat.     

Arterial-phase three-dimensional gadolinium magnetic resonance angiography of the renal arteries. Strategies for timing and contrast media injection: original investigation

RATIONALE AND OBJECTIVES: The authors review different imaging and contrast-media infusion strategies for arterial-phase three-dimensional (3D) gadolinium-enhanced magnetic resonance angiography (Gd-MRA). METHODS: The influence of physicochemical factors on the infusion of contrast media, including viscosity, flow rate, inline pressure, and cannula size, is assessed. The combination of manual or automated contrast-media administration with timing-dependent or -independent 3D Gd-MRA techniques is reviewed regarding the aspects of effectiveness, robustness, image quality, and costs. RESULTS: For effective bolus delivery with high flow rates, the type and temperature of the contrast media, the size of the cannula, and an immediate saline flush must be considered. Timing-dependent techniques based on a test bolus and using automated contrast-media infusion as well as timing independent techniques such as MR SmartPrep or multiphase 3D Gd-MRA by using a manual injection with a SmartSet tubing set, are all effective procedures for arterial phase 3D Gd-MRA. CONCLUSIONS: Manual contrast-media injection with a tubing set can be used for timing-independent MRA techniques. The multiphase 3D Gd-MRA approach seems to be favorable for different MR systems, robustness, and speed.     

Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain

OBJECTIVE: This study assesses intravascular density produced by ionic and nonionic contrast material and its effect on visualization of stenoses by CT angiography. MATERIALS AND METHODS: CT angiography was performed using a 32-vessel phantom to study grades of luminal stenoses (0-100%), three lengths of stenoses (1, 3, and 5 mm), and two angles of inclination into the stenoses (45 degrees and 75 degrees). Scans were obtained with a slice thickness of 2 mm, a slice interval of 1.5 mm, a pitch of 1.0, a voltage of 120 kV, and a current of both 100 and 200 mA. Vessels were oriented parallel to the z-axis, and opacified with ionic and nonionic contrast material that had densities of 100, 150, 200, 250, 300, and 350 H. Cross-sectional luminal diameters were measured in and out of the stenoses. Edge definition and halo artifact for each vessel were graded by an investigator who was unaware of the contrast material density used. RESULTS: A contrast density of 150 H as revealed by CT angiography yielded the most accurate stenosis measurements with ionic contrast material. For nonionic contrast material, attenuation values of 150 and 200 H produced the best results on CT angiography. A density of 100 H or greater than 250 H significantly increased the error of vessel measurement (p = .001) for both types of contrast material. For the two current levels tested (100 and 200 mA), no statistical difference was found. CONCLUSION: The accuracy of CT angiography in measuring carotid stenosis depends on the luminal attenuation value. An optimum contrast density is 150 H for ionic contrast material; for nonionic contrast material, 150-200 H (at the window and level settings of 300 H and 40 H).